Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 10/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 7/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17834829 | 0.94 | L3MBTL1 (0.49) | L3MBTL1ACEACE2TSHRPPARG | |
| SCHEMBL19485713 | 0.94 | L3MBTL1 (0.51) | L3MBTL1ACEACE2TSHR | |
| SCHEMBL17834828 | 0.93 | L3MBTL1 (0.49) | L3MBTL1ACEACE2TSHR | |
| SCHEMBL17834851 | 0.93 | L3MBTL1 (0.49) | L3MBTL1ACEACE2TSHR | |
| SCHEMBL20426117 | 0.92 | L3MBTL1 (0.48) | L3MBTL1ACEACE2TSHR | |
| SCHEMBL16305979 | 0.92 | L3MBTL1 (0.48) | L3MBTL1ACEACE2TSHR | |
| SCHEMBL17834426 | 0.90 | L3MBTL1 (0.47) | L3MBTL1ACEACE2TSHR | |
| SCHEMBL17834432 | 0.90 | L3MBTL1 (0.46) | L3MBTL1ACEACE2TSHR | |
| SCHEMBL17834849 | 0.89 | L3MBTL1 (0.49) | L3MBTL1ACEACE2TSHR | |
| SCHEMBL19807162 | 0.89 | HRH3 (0.41) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | L3MBTL1 771/4885ACE 3137/4885ACE2 3162/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | L3MBTL1 579/4885ACE 2924/4885ACE2 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.